Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
2.38
Dollar change
-0.09
Percentage change
-3.64
%
IndexRUT P/E- EPS (ttm)-1.14 Insider Own25.08% Shs Outstand120.71M Perf Week-12.82%
Market Cap291.22M Forward P/E- EPS next Y-0.72 Insider Trans-0.21% Shs Float91.67M Perf Month-16.49%
Income-134.81M PEG- EPS next Q-0.17 Inst Own74.74% Short Float9.81% Perf Quarter-41.38%
Sales38.30M P/S7.60 EPS this Y58.18% Inst Trans4.06% Short Ratio4.17 Perf Half Y59.20%
Book/sh0.23 P/B10.41 EPS next Y-16.36% ROA-54.52% Short Interest8.99M Perf Year-67.88%
Cash/sh1.50 P/C1.59 EPS next 5Y- ROE-292.19% 52W Range0.80 - 9.62 Perf YTD2.59%
Dividend Est.- P/FCF- EPS past 5Y11.93% ROI-257.73% 52W High-75.26% Beta1.50
Dividend TTM- Quick Ratio3.51 Sales past 5Y12371.94% Gross Margin95.77% 52W Low196.98% ATR (14)0.26
Dividend Ex-Date- Current Ratio3.51 EPS Y/Y TTM46.52% Oper. Margin-350.30% RSI (14)30.95 Volatility7.22% 9.60%
Employees123 Debt/Eq1.18 Sales Y/Y TTM18.40% Profit Margin-352.01% Recom1.44 Target Price6.38
Option/ShortYes / Yes LT Debt/Eq0.87 EPS Q/Q69.56% Payout- Rel Volume0.42 Prev Close2.47
Sales Surprise8.73% EPS Surprise10.31% Sales Q/Q18.50% EarningsMay 09 BMO Avg Volume2.15M Price2.38
SMA20-18.77% SMA50-34.33% SMA200-8.47% Trades Volume912,459 Change-3.64%
Date Action Analyst Rating Change Price Target Change
Mar-19-24Upgrade JP Morgan Underweight → Neutral $5
Feb-29-24Upgrade Wedbush Neutral → Outperform $2 → $7
Feb-29-24Upgrade Guggenheim Neutral → Buy $7
Feb-29-24Upgrade BTIG Research Neutral → Buy $6
Dec-04-23Upgrade Citigroup Neutral → Buy $1 → $5
Jul-28-23Downgrade Robert W. Baird Outperform → Neutral $7 → $1
Jul-27-23Downgrade Wedbush Outperform → Neutral
Jul-27-23Downgrade Truist Buy → Hold
Jul-27-23Downgrade JP Morgan Neutral → Underweight
Jul-27-23Downgrade Guggenheim Buy → Neutral
May-22-24 08:00AM
May-10-24 04:36PM
03:15PM
May-09-24 11:55AM
08:05AM
06:59AM Loading…
06:59AM
May-03-24 04:30PM
May-02-24 08:00AM
Apr-04-24 04:30PM
Feb-29-24 08:41AM
Feb-28-24 09:49PM
08:10AM
07:35AM
07:00AM
Feb-27-24 08:01AM
08:00AM Loading…
Feb-21-24 08:00AM
Feb-20-24 10:00AM
Feb-01-24 08:00AM
Jan-05-24 08:01AM
Dec-01-23 04:30PM
Nov-08-23 02:42PM
12:13AM
Nov-07-23 08:10AM
07:00AM
Oct-31-23 04:30PM
08:00AM
Sep-07-23 06:30AM
Sep-06-23 07:00AM
Aug-18-23 09:35AM
Aug-16-23 09:35AM
09:40AM Loading…
Aug-08-23 09:40AM
08:00AM
Aug-04-23 04:05PM
Jul-28-23 10:13AM
03:14AM
Jul-27-23 09:34PM
01:44PM
07:06AM
Jul-13-23 09:45AM
Jul-06-23 04:05PM
Jun-22-23 11:04AM
Jun-16-23 10:43AM
02:26AM
Jun-15-23 09:32AM
07:36AM
07:30AM
Jun-13-23 06:00AM
Jun-02-23 04:05PM
May-28-23 09:06AM
May-24-23 08:00AM
May-09-23 08:35AM
07:00AM
May-04-23 04:05PM
May-03-23 08:00AM
May-02-23 08:00AM
Apr-26-23 04:05PM
Apr-19-23 02:42PM
Apr-17-23 11:07AM
Apr-06-23 04:05PM
Apr-05-23 02:00PM
Mar-16-23 11:20AM
Mar-13-23 02:00PM
07:54AM
07:30AM
Mar-10-23 07:10PM
Mar-03-23 04:05PM
Mar-02-23 08:55PM
Mar-01-23 05:24AM
Feb-28-23 11:51PM
07:00AM
Feb-21-23 08:00AM
Feb-03-23 04:05PM
Feb-02-23 08:00AM
Feb-01-23 08:00AM
Jan-25-23 08:00AM
Jan-20-23 03:16PM
Jan-16-23 02:18AM
Jan-06-23 04:05PM
07:00AM
Dec-31-22 07:42AM
Dec-23-22 12:46PM
10:08AM
Dec-22-22 04:08PM
04:05PM
Dec-14-22 08:00AM
Dec-02-22 04:05PM
Nov-08-22 08:00AM
Nov-07-22 08:25AM
07:00AM
Nov-04-22 04:05PM
Oct-31-22 08:00AM
Oct-30-22 10:13AM
Oct-17-22 09:40AM
Oct-06-22 04:05PM
Oct-04-22 04:05PM
Sep-30-22 08:02AM
Sep-12-22 08:00AM
Sep-06-22 08:00AM
Sep-02-22 04:05PM
Sep-01-22 10:17AM
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Protopapas AnnaDirectorJan 16 '24Sale2.7129,39979,671125,153Jan 17 05:21 PM
Lowinger Timothy BSVP, Chief Sci.&Tech. OfficerJan 16 '24Sale2.7110,40928,208199,329Jan 17 05:19 PM
DeSchuytner BrianSVP, COO & CFOJan 16 '24Sale2.719,32725,27654,511Jan 17 05:18 PM
Mandelia AshishVP, Chief Accounting OfficerJan 16 '24Sale2.715,02513,61823,328Jan 17 05:20 PM
Carvajal AlejandraSVP, Chief Legal OfficerJan 16 '24Sale2.714,38111,87327,403Jan 17 05:18 PM
Bala MohanSVP, Chief Development OfficerJan 16 '24Sale2.713,4319,29814,052Jan 17 05:16 PM
MISRA TUSHARSVP, Chief Manuf. OfficerJan 16 '24Sale2.713,3579,09717,966Jan 17 05:21 PM
Lowinger Timothy BSVP, Chief Sci.&Tech. OfficerJan 15 '24Option Exercise0.0015,2080209,738Jan 17 05:19 PM
DeSchuytner BrianSVP, COO & CFOJan 15 '24Option Exercise0.0010,208063,838Jan 17 05:18 PM
Protopapas AnnaDirectorJan 15 '24Option Exercise0.0038,9580154,552Jan 17 05:21 PM
Mandelia AshishVP, Chief Accounting OfficerJan 15 '24Option Exercise0.005,352028,353Jan 17 05:20 PM
Mandelia AshishVP, Chief Accounting OfficerJan 14 '24Option Exercise0.004,783023,001Jan 17 05:20 PM
MISRA TUSHARSVP, Chief Manuf. OfficerJan 14 '24Option Exercise0.001,458021,323Jan 17 05:21 PM
Protopapas AnnaDirectorJan 14 '24Option Exercise0.0016,7500115,594Jan 17 05:21 PM
Carvajal AlejandraSVP, Chief Legal OfficerJan 14 '24Option Exercise0.002,500031,784Jan 17 05:18 PM
DeSchuytner BrianSVP, COO & CFOJan 14 '24Option Exercise0.006,250055,630Jan 17 05:18 PM
Lowinger Timothy BSVP, Chief Sci.&Tech. OfficerJan 14 '24Option Exercise0.004,7920194,530Jan 17 05:19 PM
Lowinger Timothy BSVP, Chief Sci.&Tech. OfficerJan 13 '24Option Exercise0.009,3750189,738Jan 17 05:19 PM
DeSchuytner BrianSVP, COO & CFOJan 13 '24Option Exercise0.0010,000047,380Jan 17 05:18 PM
Carvajal AlejandraSVP, Chief Legal OfficerJan 13 '24Option Exercise0.008,958029,284Jan 17 05:18 PM
Bala MohanSVP, Chief Development OfficerJan 13 '24Option Exercise0.008,750017,483Jan 17 05:16 PM
Protopapas AnnaDirectorJan 13 '24Option Exercise0.0031,250098,844Jan 17 05:21 PM
MISRA TUSHARSVP, Chief Manuf. OfficerJan 13 '24Option Exercise0.007,083019,865Jan 17 05:21 PM
Mandelia AshishVP, Chief Accounting OfficerJan 13 '24Option Exercise0.002,645018,218Jan 17 05:20 PM
Bala MohanSVP, Chief Development OfficerOct 26 '23Sale1.131,9122,1618,733Oct 27 04:07 PM
Bala MohanSVP, Chief Development OfficerOct 25 '23Option Exercise0.006,250010,645Oct 27 04:07 PM
MISRA TUSHARSVP, Chief Manuf. OfficerAug 17 '23Sale1.181,9082,25111,507Aug 18 04:01 PM
MISRA TUSHARSVP, Chief Manuf. OfficerAug 16 '23Option Exercise0.006,250013,415Aug 18 04:01 PM